BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 17339347)

  • 1. Immunogenicity of Anaplasma marginale type IV secretion system proteins in a protective outer membrane vaccine.
    Lopez JE; Palmer GH; Brayton KA; Dark MJ; Leach SE; Brown WC
    Infect Immun; 2007 May; 75(5):2333-42. PubMed ID: 17339347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG and IgG2 antibodies from cattle naturally infected with Anaplasma marginale recognize the recombinant vaccine candidate antigens VirB9, VirB10, and elongation factor-Tu.
    Araújo FR; Costa CM; Ramos CA; Farias TA; Souza II; Melo ES; Elisei C; Rosinha GM; Soares CO; Fragoso SP; Fonseca AH
    Mem Inst Oswaldo Cruz; 2008 Mar; 103(2):186-90. PubMed ID: 18425271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale.
    Zhao L; Mahony D; Cavallaro AS; Zhang B; Zhang J; Deringer JR; Zhao CX; Brown WC; Yu C; Mitter N; Middelberg AP
    PLoS One; 2016; 11(4):e0154295. PubMed ID: 27115492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subdominant Outer Membrane Antigens in Anaplasma marginale: Conservation, Antigenicity, and Protective Capacity Using Recombinant Protein.
    Ducken DR; Brown WC; Alperin DC; Brayton KA; Reif KE; Turse JE; Palmer GH; Noh SM
    PLoS One; 2015; 10(6):e0129309. PubMed ID: 26079491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4(+) T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge.
    Brown WC; Shkap V; Zhu D; McGuire TC; Tuo W; McElwain TF; Palmer GH
    Infect Immun; 1998 Nov; 66(11):5406-13. PubMed ID: 9784551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and long-term disappearance of CD4+ T lymphocyte responses specific for Anaplasma marginale major surface protein-2 (MSP2) in MSP2 vaccinates following challenge with live A. marginale.
    Abbott JR; Palmer GH; Kegerreis KA; Hetrick PF; Howard CJ; Hope JC; Brown WC
    J Immunol; 2005 Jun; 174(11):6702-15. PubMed ID: 15905510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of B-cell epitopes in the N-terminal repeated peptides of Anaplasma marginale major surface protein 1a and characterization of the humoral immune response of cattle immunized with recombinant and whole organism antigens.
    Garcia-Garcia JC; de la Fuente J; Kocan KM; Blouin EF; Halbur T; Onet VC; Saliki JT
    Vet Immunol Immunopathol; 2004 Apr; 98(3-4):137-51. PubMed ID: 15010223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel antigenic proteins in a complex Anaplasma marginale outer membrane immunogen by mass spectrometry and genomic mapping.
    Lopez JE; Siems WF; Palmer GH; Brayton KA; McGuire TC; Norimine J; Brown WC
    Infect Immun; 2005 Dec; 73(12):8109-18. PubMed ID: 16299305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale.
    Zhao L; Cavallaro AS; Wibowo D; Zhang B; Zhang J; Mitter N; Yu C; Zhao CX; Middelberg AP
    Vaccine; 2017 Jan; 35(1):77-83. PubMed ID: 27890399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major histocompatibility complex class II DR-restricted memory CD4(+) T lymphocytes recognize conserved immunodominant epitopes of Anaplasma marginale major surface protein 1a.
    Brown WC; McGuire TC; Mwangi W; Kegerreis KA; Macmillan H; Lewin HA; Palmer GH
    Infect Immun; 2002 Oct; 70(10):5521-32. PubMed ID: 12228278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subdominant antigens in bacterial vaccines: AM779 is subdominant in the Anaplasma marginale outer membrane vaccine but does not associate with protective immunity.
    Albarrak SM; Brown WC; Noh SM; Reif KE; Scoles GA; Turse JE; Norimine J; Ueti MW; Palmer GH
    PLoS One; 2012; 7(9):e46372. PubMed ID: 23029498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breadth of the CD4+ T cell response to Anaplasma marginale VirB9-1, VirB9-2 and VirB10 and MHC class II DR and DQ restriction elements.
    Morse K; Norimine J; Hope JC; Brown WC
    Immunogenetics; 2012 Jul; 64(7):507-23. PubMed ID: 22361828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale.
    Morse K; Norimine J; Palmer GH; Sutten EL; Baszler TV; Brown WC
    Infect Immun; 2012 Jan; 80(1):215-27. PubMed ID: 22038917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypervariable region of Anaplasma marginale major surface protein 2 (MSP2) contains multiple immunodominant CD4+ T lymphocyte epitopes that elicit variant-specific proliferative and IFN-gamma responses in MSP2 vaccinates.
    Brown WC; Brayton KA; Styer CM; Palmer GH
    J Immunol; 2003 Apr; 170(7):3790-8. PubMed ID: 12646645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplasma marginale outer membrane protein vaccine candidates are conserved in North American and South African strains.
    Hove P; Brayton KA; Liebenberg J; Pretorius A; Oosthuizen MC; Noh SM; Collins NE
    Ticks Tick Borne Dis; 2020 Jul; 11(4):101444. PubMed ID: 32336660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VirB10 vaccination for protection against Anaplasma phagocytophilum.
    Crosby FL; Lundgren AM; Hoffman C; Pascual DW; Barbet AF
    BMC Microbiol; 2018 Dec; 18(1):217. PubMed ID: 30563470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput identification of T-lymphocyte antigens from Anaplasma marginale expressed using in vitro transcription and translation.
    Lopez JE; Beare PA; Heinzen RA; Norimine J; Lahmers KK; Palmer GH; Brown WC
    J Immunol Methods; 2008 Mar; 332(1-2):129-41. PubMed ID: 18243240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of hypothetical highly conserved proteins as novel antigens in Anaplasma marginale.
    Nuñez PA; Moretta R; Ruybal P; Wilkowsky S; Farber MD
    Curr Microbiol; 2014 Mar; 68(3):269-77. PubMed ID: 24126603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge.
    Sarli M; Novoa MB; Mazzucco MN; Signorini ML; Echaide IE; de Echaide ST; Primo ME
    PLoS One; 2020; 15(2):e0229301. PubMed ID: 32084216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of IgG2-specific antigens in Mexican Anaplasma marginale strains.
    Barigye R; García-Ortiz MA; Rojas Ramírez EE; Rodríguez SD
    Ann N Y Acad Sci; 2004 Oct; 1026():84-94. PubMed ID: 15604474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.